Acurx Pharmaceuticals, LLC (“Acurx” or the “Company”), a clinical stage, privately-held biopharmaceutical company focused on developing new antibiotics for difficult-to-treat bacterial infections, announced today that the Food and Drug Administration (FDA) has granted Fast Track designation for ACX-362E, an investigational new treatment for Clostridium difficile Infection (CDI).
January 16, 2019
· 5 min read